Drug Approval | November 22, 2023
Lupin receives tentative approval from USFDA for Dapagliflozin Tablets
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Distributes Ayushman cards to several beneficiaries
Evinova will operate as a separate health-tech business within AstraZeneca
Decision on EU marketing authorisation expected for momelotinib by early 2024
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
The product will be manufactured at Lupin’s Nagpur facility in India
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated
